Want to see HK:2696 full AI Analyst Report?
Shanghai Henlius Biotech, Inc. Class H (2696) Revenue
Shanghai Henlius Biotech, Inc. Class H Revenue
Shanghai Henlius Biotech, Inc. Class H had a revenue of 1.79B in the quarter ending Jun 30, 2026, with 0.00%. This bring the company's revenue in the last twelve months to 7.44B, Increased 5.45%. In the fiscal year ending Dec 31, 2025, Shanghai Henlius Biotech, Inc. Class H had annual revenue of 6.67B with 16.46% growth.
- Revenue (ttm)
- 7.44B
- Revenue Growth
- 32.63%
- P/S Ratio
- 4.01
- Revenue/Employee
- HKD 1,633,177
- Employees
- 4,082
- Market Cap
- HKD 26.75B
Revenue Chart
Shanghai Henlius Biotech, Inc. Class H Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.67B | 942.18M | 16.46% |
| Dec 31, 2024 | 5.72B | 329.54M | 6.11% |
| Dec 31, 2023 | 5.39B | 2.18B | 67.82% |
| Dec 31, 2022 | 3.21B | 1.53B | 91.07% |
| Dec 31, 2021 | 1.68B | 1.09B | 186.34% |
| Dec 31, 2020 | 587.59M | 496.66M | 546.20% |
| Dec 31, 2019 | 90.93M | 83.51M | 1125.29% |
| Dec 31, 2018 | 7.42M | -26.49M | -78.12% |
| Dec 31, 2017 | 33.91M | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.